What is Aniclindan?
Aniclindan belongs to the family of medicines called antibiotics.
Topical Aniclindan is used to help control acne. It may be used alone or with one or more other medicines that are used on the skin or taken by mouth for acne.
Topical Aniclindan may also be used for other problems as determined by your doctor.
Aniclindan is available only with your doctor's prescription.
Aniclindan indications
Aniclindan Pediatric (Aniclindan palmitate HCl) is indicated in the treatment of serious infections caused by susceptible anaerobic bacteria.
Aniclindan is also indicated in the treatment of serious infections due to susceptible strains of streptococci, pneumococci and staphylococci. Its use should be reserved for penicillin-allergic patients or other patients for whom, in the judgment of the physician, a penicillin is inappropriate. Because of the risk of colitis, as described in the WARNING box, before selecting Aniclindan the physician should consider the nature of the infection and the suitability of less toxic alternatives (e.g., erythromycin).
Anaerobes: Serious respiratory tract infections such as empyema, anaerobic pneumonitis and lung abscess; serious skin and soft tissue infections; septicemia; intra-abdominal infections such as peritonitis and intra-abdominal abscess (typically resulting from anaerobic organisms resident in the normal gastrointestinal tract); infections of the female pelvis and genital tract such as endometritis, nongonococcal tubo-ovarian abscess, pelvic cellulitis and postsurgical vaginal cuff infection.
Streptococci: Serious respiratory tract infections; serious skin and soft tissue infections.
Staphylococci: Serious respiratory tract infections; serious skin and soft tissue infections.
Pneumococci: Serious respiratory tract infections.
Bacteriologic studies should be performed to determine the causative organisms and their susceptibility to Aniclindan.
In Vitro Susceptibility Testing
A standardized disk testing procedure2 is recommended for determining susceptibility of aerobic bacteria to Aniclindan. A description is contained in the Aniclindan® Susceptibility Disk (Aniclindan) insert. Using this method, the laboratory can designate isolates as resistant, intermediate, or susceptible. Tube or agar dilution methods may be used for both anaerobic and aerobic bacteria. When the directions in the Aniclindan® Susceptibility Powder insert are followed, an MIC (minimal inhibitory concentration) of 1.6 mcg/mL may be considered susceptible; MICs of 1.6 to 4.8 mcg/mL may be considered intermediate and MICs greater than 4.8 mcg/mL may be considered resistant.
Aniclindan Susceptibility Disks 2 mcg. See package insert for use.
Aniclindan Susceptibility Powder 20 mg. See package insert for use.
For anaerobic bacteria the minimal inhibitory concentration (MIC) of Aniclindan can be determined by agar dilution and broth dilution (including microdilution) techniques. If MICs are not determined routinely, the disk broth method is recommended for routine use. THE KIRBY-BAUER DISK DIFFUSION METHOD AND ITS INTERPRETIVE STANDARDS ARE NOT RECOMMENDED FOR ANAEROBES.
To reduce the development of drug-resistant bacteria and maintain the effectiveness of Aniclindan Pediatric and other antibacterial drugs, Aniclindan Pediatric should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy.
How should I use Aniclindan?
Use Aniclindan suppositories as directed by your doctor. Check the label on the medicine for exact dosing instructions.
- Aniclindan suppositories comes with an extra patient information sheet called a Medication Guide. Read it carefully. Read it again each time you get Aniclindan suppositories refilled.
- Do not use this product if the foil pouch that contains Clindamycin suppositories is torn, open, or not sealed all the way.
- Insert into vagina at bedtime for 3 consecutive days.
- Once inside the vagina, Aniclindan suppositories melts. Lie down as soon as possible to minimize leakage.
- Aniclindan suppositories works best if it is used at the same time each day.
- To clear up your infection completely, use Aniclindan suppositories for the full course of treatment. Keep using it even if you feel better in a few days.
- If you miss a dose of Aniclindan suppositories and you are using it regularly, use it as soon as possible. If several hours have passed or if it is nearing time for the next dose, do not double the dose to catch up, unless advised by your health care provider. Do not use 2 doses at once. If more than one dose is missed, contact your doctor or pharmacist.
Ask your health care provider any questions you may have about how to use Aniclindan suppositories.
Uses of Aniclindan in details
Use: Labeled Indications
Bone and joint infections: Treatment of bone and joint infections, including acute hematogenous osteomyelitis caused by Staphylococcus aureus and as adjunctive therapy in the surgical treatment of chronic bone and joint infections caused by susceptible organisms.
Gynecological infections: Treatment of gynecologic infections, including endometritis, nongonococcal tubo-ovarian abscess, pelvic cellulitis, and postsurgical vaginal cuff infection caused by susceptible anaerobes.
Intraabdominal infections: Treatment of intraabdominal infections, including peritonitis and intraabdominal abscess caused by susceptible anaerobic organisms.
Lower respiratory tract infections: Treatment of lower respiratory tract infections, including pneumonia, empyema, and lung abscess caused by susceptible anaerobes, Streptococcus pneumoniae, other streptococci (except Enterococcus faecalis), and S. aureus.
Septicemia: Treatment of septicemia caused by S. aureus, streptococci (except E. faecalis), and susceptible anaerobes.
Skin and soft tissue infection: Treatment of skin and soft tissue infection caused by Streptococcus pyogenes, S. aureus, and susceptible anaerobes.
Off Label Uses
Anthrax
Based on the Centers for Disease Control and Prevention (CDC) expert panel meetings on prevention and treatment of anthrax in adults, Aniclindan is an effective and acceptable alternative for postexposure prophylaxis or treatment of cutaneous anthrax; it is also a first-line option, in combination with other antimicrobials, for the treatment of systemic anthrax. Alternative regimens have also been suggested for other patient populations with anthrax, including injectable drug users who develop injectional anthrax.
Streptococcal (group A) pharyngitis and chronic carriage
Based on the IDSA guidelines for the diagnosis and management of group A streptococcal pharyngitis, Aniclindan is an effective and recommended alternative agent for the treatment of streptococcal pharyngitis and an option for treatment of chronic group A streptococcal carriage.
Surgical prophylaxis
Based on the American Society of Health-System Pharmacists (ASHP) clinical practice guidelines for antimicrobial prophylaxis in surgery, Aniclindan, given as an alternative antibiotic in patients with beta-lactam allergy requiring surgical prophylaxis, is effective and recommended for a number of surgical procedures.
Toxoplasma gondii encephalitis and pneumonitis (treatment/long-term maintenance)
Based on the US Department of Health and Human Services guidelines for the prevention and treatment of opportunistic infections in HIV-infected adults and adolescents and the American Society of Transplantation Infectious Diseases Community of Practice guidelines on parasitic infections in solid organ transplantation, Aniclindan (with pyrimethamine and leucovorin) is an effective and recommended alternative regimen for the treatment and long-term maintenance therapy of Toxoplasma gondii encephalitis and pneumonitis.
Aniclindan description
Aniclindan is a semisynthetic antibiotic produced by a 7(S)-chloro-substitution of the 7(R)-hydroxyl group of the parent compound lincomycin.
Aniclindan phosphate is a water soluble ester of Aniclindan and phosphoric acid.
Aniclindan phosphate is L-threo-α-D-galacto-Octopyranoside, methyl 7-chloro-6, 7, 8-trideoxy-6-[[(1-methyl-4-propyl-2-pyrrolidinyl)carbonyl] amino]-1-thio-, 2-(dihydrogen phosphate), (2S-trans)-.
The molecular formula is C18H34CIN2O8PS and the molecular weight is 504.96.
Aniclindan hydrochloride is the hydrated hydrochloride salt of Aniclindan. Aniclindan hydrochloride is Methyl 7-chloro-6, 7, 8-trideoxy-6-(1-methyl-trans-4-propyl-L-2-pyrrolidinecarboxamido)-1-thio-L-threo-α-D-galacto-octopyranoside monohydrochloride.
Aniclindan palmitate hydrochloride is a water soluble salt of ester of Aniclindan and palmitic acid. Aniclindan palmitate hydrochloride is Methyl 7-chloro-6, 7, 8-trideoxy-6-(1-methyl-trans-4-propyl-L-2-pyrrolidinecarboxamido)-1-thio-L-threo-α-D-galacto-octopyranoside 2-palmitate monohydrochloride.
Aniclindan dosage
Aniclindan Dosage
Generic name: Aniclindan PHOSPHATE 10mg in 1g
Dosage form: aerosol, foam
The information at Drugs.com is not a substitute for medical advice. Always consult your doctor or pharmacist.
Aniclindan Foam is for topical use only, and not for oral, ophthalmic, or intravaginal use.
Apply Aniclindan Foam once daily to affected areas after the skin is washed with mild soap and allowed to fully dry. Use enough to cover the entire affected area.
If there has been no improvement after 6 to 8 weeks or if the condition becomes worse, treatment should be discontinued.
The contents of Aniclindan Foam are flammable; avoid fire, flame and/or smoking during and immediately following application.
More about Aniclindan (Aniclindan topical)
- Side Effects
- During Pregnancy or Breastfeeding
- Dosage Information
- Drug Interactions
- Support Group
- Pricing & Coupons
- 0 Reviews - Add your own review/rating
- Generic Availability
Consumer resources
- Aniclindan
- Aniclindan foam
- Aniclindan
Topical (Advanced Reading)
- Other brands: Aniclindan T, Clindagel, Aniclindan Vaginal, Clindesse, More (8) »
Professional resources
- Aniclindan (FDA)
- Aniclindan Phosphate topical (AHFS Monograph)
Related treatment guides
- Acne
- Perioral Dermatitis
Aniclindan interactions
See also:
What other drugs will affect Aniclindan?
With simultaneous use of Aniclindan with theophylline, aminophylline, caffeine, there is an increase in their concentration in blood plasma and thus increases the risk of toxic effects.
Erythromycin increases the concentrations of cyclosporine in the blood plasma and may increase the risk of nephrotoxicity.
Drugs that block tubular secretion prolongs T1/2 of erythromycin.
Incompatible with lincomycin, Aniclindan and chloramphenicol (antagonism).
Aniclindan reduces the bactericidal action of beta-lactam antibiotics (penicillins, cephalosporins, carbapenems).
With simultaneous use of erythromycin increases the concentration of theophylline.
At the same time receiving chemotherapy, which is carried metabolism in the liver (carbamazepine, valproic acid, hexobarbital, phenytoin, alfentanil, dizopiramid, lovastatin, bromocriptine), may increase the concentration of these drugs in plasma (an inhibitor of microsomal liver enzymes).
IV injection of erythromycin increases the effects of ethanol (accelerating gastric emptying and decrease the duration of alcohol dehydrogenase in the gastric mucosa).
Erythromycin reduces the clearance of triazolam and midazolam and therefore may increase the pharmacological effects of benzodiazepines.
At the same time taking with terfenadine or astemizole may develop arrhythmias (fibrillation and ventricular flutter, ventricular tachycardia, until death); with dihydroergotamine or non hydrated ergot alkaloids may vasoconstriction to spasm, dysesthesia.
With simultaneous application Aniclindan slows elimination (increases the effect) of methylprednisolone, felodipine and anticoagulants of cumarine series.
In a joint appointment with lovastatin increased rhabdomyolysis.
Erythromycin increases the bioavailability of digoxin.
Erythromycin reduces the effectiveness of hormonal contraceptives.
Aniclindan side effects
See also:
What are the possible side effects of Aniclindan?
Clinical Trials Experience
Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in clinical practice.
A total of 439 subjects with mild to moderate acne vulgaris were treated once daily for 12 weeks with Aniclindan Foam.
The incidence of adverse reactions occurring in ≥1% of the subjects in clinical trials comparing Aniclindan Foam and its vehicle is presented in Table 1.
Table 1: Adverse Reactions Occurring in ≥1% of Subjects
| Adverse Reactions | Number (%) of Subjects | |
| Aniclindan Foam N = 439 | Vehicle Foam N = 154 | |
| Headache | 12 (3%) | 1 (1%) |
| Application site burning | 27 (6%) | 14 (9%) |
| Application site pruritus | 5 (1%) | 5 (3%) |
| Application site dryness | 4 (1%) | 5 (3%) |
| Application site reaction, not otherwise specified | 3 (1%) | 4 (3%) |
In a contact sensitization study, none of the 203 subjects developed evidence of allergic contact sensitization to Aniclindan Foam.
Postmarketing Experience
The following adverse reactions have been identified during post approval use of Aniclindan Foam: application site pain, application site erythema, diarrhea, urticaria, abdominal pain, hypersensitivity, rash, abdominal discomfort, nausea, seborrhea, application site rash, dizziness, pain of skin, colitis (including pseudomembranous colitis), and hemorrhagic diarrhea. Because these reactions are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure.
Abdominal pain and gastrointestinal disturbances, as well as gram-negative folliculitis, have also been reported in association with the use of topical formulations of Aniclindan.
Orally and parenterally administered Aniclindan have been associated with severe colitis, which may end fatally.
Aniclindan contraindications
See also:
What is the most important information I should know about Aniclindan?
You should not use this medication if you are allergic to Aniclindan or lincomycin (Bactramycin, L-Mycin, Lincocin).
Do not take Aniclindan together with erythromycin (E.E.S., EryPed, Ery-Tab, Erythrocin, Pediazole, and others).
Before using Aniclindan, tell your doctor if you have kidney disease, liver disease, an intestinal disorder such as colitis or Crohn's disease, or a history of asthma, eczema, or allergic skin reaction.
Take this medicine for the full prescribed length of time. Your symptoms may improve before the infection is completely cleared. Skipping doses may also increase your risk of further infection that is resistant to antibiotics. Aniclindan will not treat a viral infection such as the common cold or flu.
Antibiotic medicines can cause diarrhea, which may be a sign of a new infection. If you have diarrhea that is watery or bloody, stop taking Aniclindan and call your doctor. Do not use anti-diarrhea medicine unless your doctor tells you to.
To be sure this medication is not causing harmful effects, your blood may need to be tested often. Your kidney or liver function may also need to be tested. Visit your doctor regularly.
If you need surgery, tell the surgeon ahead of time that you are using Aniclindan. You may need to stop using the medicine for a short time.
Active ingredient matches for Aniclindan:
Clindamycin in Germany, Poland.
List of Aniclindan substitutes (brand and generic names) | Sort by popularity |
| Unit description / dosage (Manufacturer) | Price, USD |
| Anich-3 (India) | |
| ANICH-3 softgel 10's (Ind-Swift) | $ 2.24 |
| Antirobe 150 für Hunde (Switzerland) | |
| Antirobe 150 mg für Hunde (Austria) | |
| Antirobe 25 für Hunde (Switzerland) | |
| Antirobe 25mg (Netherlands) | |
| Antirobe 300 für Hunde (Switzerland) | |
| Antirobe 75 für Hunde (Switzerland) | |
| Antirobe Aquadrops | |
| Liquid; Oral; Clindamycin Hydrochloride 25 mg / ml | |
| Ao Di (China) | |
| Ao Li Xian (China) | |
| Apex Clindamycin 150 (Australia) | |
| Apo-Clindamycin (Canada) | |
| Capsule; Oral; Clindamycin Hydrochloride 150 mg | |
| Capsule; Oral; Clindamycin Hydrochloride 300 mg | |
| Apo-clindamycin capsule 300 mg (Apotex Inc (Canada)) | |
| Apo-clindamycin capsule 150 mg (Apotex Inc (Canada)) | |
| Apomiclin (Mexico) | |
| Arfarel (Cyprus) | |
| Auro-Clindamycin (Canada) | |
| Auro-clindamycin capsule 300 mg (Auro Pharma Inc (Canada)) | |
| Auro-clindamycin capsule 150 mg (Auro Pharma Inc (Canada)) | |
| Axcel Clindamycin (Hong Kong) | |
| Axcel Clindamycin topical soln 1% w/v 30 mL x 1's (Kotra Pharma) | |
| B.B. (Taiwan) | |
| B.B. 150 mg x 1000's | |
| B.B. 300 mg x 1000's | |
| B.B. 150 mg/1 mL x 2 mL x 10's | |
| Bactemicina (Costa Rica, Dominican Republic, Guatemala, Panama) | |
| Bang Wei Lin Xin (China) | |
| Basocin (Germany) | |
| Basocin 1% (Germany) | |
| Bei He (China) | |
| Bexon (Argentina, Colombia) | |
| Bin Ke (China) | |
| Bioclindax (Venezuela) | |
| Biocline (Turkey) | |
| Biodaclin (Mexico) | |
| Capsule; Oral; Cefepime Hydrochloride Monohydrate 300 mg (Rayere) | |
| Gel; Topical; Clindamycin Phosphate 1% (Rayere) | |
| Injectable; Injection; Clindamycin Phosphate 150 mg / ml (Rayere) | |
| Biodasin (Indonesia) | |
| Biodasin 150 mg x 5 x 10's (Promed) | |
| Biodasin 300 mg x 5 x 10's (Promed) | $ 34.10 |
| Bioex | |
| Bioex Skin 15 gm Cream (Nirix Derma) | $ 1.43 |
| Biolinx (India) | |
| Biolinx 300mg CAP / 50 (Biosciences-Pharmakon) | $ 8.13 |
| 300 mg x 10x5 (Biosciences-Pharmakon) | $ 8.13 |
| Biolinx 300 mg Capsule (Biosciences-Pharmakon) | $ 0.16 |
| BIOLINX cap 300 mg x 10's (Biosciences-Pharmakon) | $ 1.63 |
See 2128 substitutes for Aniclindan | |
References
- PubChem. "clindamycin". https://pubchem.ncbi.nlm.nih.gov/com... (accessed September 17, 2018).
- DrugBank. "clindamycin". http://www.drugbank.ca/drugs/DB01190 (accessed September 17, 2018).
- MeSH. "Protein Synthesis Inhibitors". https://www.ncbi.nlm.nih.gov/mesh/68... (accessed September 17, 2018).
Reviews
The results of a survey conducted on ndrugs.com for Aniclindan are given in detail below. The results of the survey conducted are based on the impressions and views of the website users and consumers taking Aniclindan. We implore you to kindly base your medical condition or therapeutic choices on the result or test conducted by a physician or licensed medical practitioners.User reports
Consumer reported useful
No survey data has been collected yetConsumer reported price estimates
No survey data has been collected yetConsumer reported time for results
No survey data has been collected yetConsumer reported age
No survey data has been collected yetConsumer reviews
There are no reviews yet. Be the first to write one! |
Information checked by Dr. Sachin Kumar, MD Pharmacology
